不同种族和族裔少数群体头颈癌生存者的结局差异
基于2007至2016年SEER数据库的回顾性队列研究,纳入21966例非西班牙裔黑人、西班牙裔、亚裔/太平洋岛民及美洲印第安/阿拉斯加原住民头颈癌患者,比较其生存差异及与就诊分期的非临床因素。调整协变量后,西班牙裔和亚裔/太平洋岛民的头颈癌特异性死亡风险低于非西班牙裔黑人,黑人患者结局最差且不能完全由分期解释。
要点
- 西班牙裔头颈癌特异性死亡风险低于非西班牙裔黑人(sdHR 0.89;95%CI 0.83-0.95)。
- 亚裔/太平洋岛民头颈癌特异性死亡风险低于非西班牙裔黑人(sdHR 0.85;95%CI 0.78-0.93)。
- 非西班牙裔黑人极低社会经济地位比例最高(37.7%),粗5年总生存率最低(46%)。
核心结论
- 在仅纳入种族和族裔少数群体头颈癌患者的队列中,黑人患者结局显著更差,且不能完全由就诊分期解释。
- 可能存在未探索的多水平因素与健康社会决定因素及头颈癌结局差异相关。
研究设计与样本
- 研究为基于人群的回顾性队列研究,使用2007至2016年监测、流行病学和最终结果(SEER)数据库。
- 纳入非西班牙裔黑人、亚裔/太平洋岛民、美洲印第安/阿拉斯加原住民及西班牙裔头颈癌患者,共21966例,平均(SD)年龄56.02(11.16)岁,女性6072例(27.6%)。
- 数据分析时间为2020年12月至2021年5月。
主要发现
- 非西班牙裔黑人9229例(42.0%),西班牙裔6893例(31.4%),亚裔/太平洋岛民5342例(24.3%),美洲印第安/阿拉斯加原住民502例(2.3%)。
- 黑人患者极低社会经济地位比例最高(3482例[37.7%]),粗5年总生存率最低(46%)。
- 与非西班牙裔黑人相比,西班牙裔头颈癌特异性死亡的风险比低11%(sdHR 0.89;95%CI 0.83-0.95)。
- 与非西班牙裔黑人相比,亚裔/太平洋岛民头颈癌特异性死亡的风险比低15%(sdHR 0.85;95%CI 0.78-0.93)。
- 与非西班牙裔黑人相比,美洲印第安/阿拉斯加原住民头颈癌特异性死亡风险呈较低趋势(sdHR 0.85;95%CI 0.71-1.01)。
关键数值与推荐
- 主要结局为至事件时间指标:头颈癌特异性死亡和全因死亡,以及就诊分期。
- 协变量包括非临床因素(诊断时年龄、性别、种族和族裔、保险状态、婚姻状态及复合社会经济地位)和临床因素(分期、肿瘤部位、化疗、放疗和手术)。
- 采用Cox回归模型调整协变量与全因死亡风险的关联,采用Fine和Gray竞争风险比例风险模型估计协变量与头颈癌特异性死亡风险的关联。
- 采用比例对数优势序数逻辑回归识别与就诊分期相关的非临床因素。
- 种族、性别、保险、婚姻状态和社会经济地位始终与全因死亡、头颈癌特异性死亡及就诊分期相关,非西班牙裔黑人结局较其他种族和族裔少数群体更差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Approximately 1 in 5 new patients with head and neck cancer (HNC) in the US belong to racial and ethnic minority groups, but their survival rates are worse than White individuals. However, because most studies compare Black vs White patients, little is known about survival differences among members of racial and ethnic minority groups. OBJECTIVE: To describe differential survival and identify nonclinical factors associated with stage of presentation among patients with HNC belonging to racial and ethnic minority groups. DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study used data from the 2007 to 2016 Surveillance, Epidemiology, and End Results (SEER) database and included non-Hispanic Black, Asian Pacific Islander, American Indian/Alaska Native, and Hispanic patients with HNC. The data were analyzed from December 2020 to May 2021. MAIN OUTCOMES AND MEASURES: Outcomes were time to event measures: (HNC-specific and all-cause mortality) and stage of presentation. Covariates included nonclinical (age at diagnosis, sex, race and ethnicity, insurance status, marital status, and a composite socioeconomic status [SES]) and clinical factors (stage, cancer site, chemotherapy, radiation, and surgery). A Cox regression model was used to adjust associations of covariates with the hazard of all-cause death, and a Fine and Gray competing risks proportional hazards model was used to estimate associations of covariates with the hazard of HNC-specific death. A proportional log odds ordinal logistic regression identified which nonclinical factors were associated with stage of presentation. RESULTS: There were 21 966 patients with HNC included in the study (mean [SD] age, 56.02 [11.16] years; 6072 women [27.6%]; 9229 [42.0%] non-Hispanic Black, 6893 [31.4%] Hispanic, 5342 [24.3%] Asian/Pacific Islander, and 502 [2.3%] American Indian/Alaska Native individuals). Black patients had highest proportion with very low SES (3482 [37.7%]) and the lowest crude 5-year overall survival (46%). After adjusting for covariates, Hispanic individuals had an 11% lower subdistribution hazard ratio (sdHR) of HNC-specific mortality (sdHR, 0.89; 95% CI, 0.83-0.95), 15% lower risk for Asian/Pacific Islander individuals (sdHR, 0.85; 95% CI, 0.78-0.93), and a trending lower risk for American Indian/Alaska Native individuals (sdHR, 0.85; 95% CI, 0.71-1.01), compared with non-Hispanic Black individuals. Race, sex, insurance, marital status, and SES were consistently associated with all-cause mortality, HNC-specific mortality, and stage of presentation, with non-Hispanic Black individuals faring worse compared with individuals of other racial and ethnic minority groups. CONCLUSIONS AND RELEVANCE: In this cohort study that included only patients with HNC who were members of racial and ethnic minority groups, Black patients had significantly worse outcomes that were not completely explained by stage of presentation. There may be unexplored multilevel factors that are associated with social determinants of health and disparities in HNC outcomes.
引用
- Taylor DB, Osazuwa-Peters OL, Okafor SI, et al. Differential Outcomes Among Survivors of Head and Neck Cancer Belonging to Racial and Ethnic Minority Groups. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 34940784. doi:10.1001/jamaoto.2021.3425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。